CASI Pharmaceuticals (CASIF) Current Deferred Revenue (2021)
CASI Pharmaceuticals (CASIF) reported Current Deferred Revenue of $2.8 million for Q4 2021.
CASI Pharmaceuticals (CASIF) Current Deferred Revenue (2021) Analysis & Trends
CASI Pharmaceuticals has reported Current Deferred Revenue for 1 years, with the latest figure at $2.8 million in Q4 2021.
- For the quarter ending Q4 2021, Current Deferred Revenue changed N/A year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2021 stood at $2.8 million (changed N/A YoY), and the FY2021 full-year result was $2.8 million, changed N/A from the prior year.
- Current Deferred Revenue for Q4 2021 stood at $2.8 million.
- The five-year high for Current Deferred Revenue was $2.8 million in Q4 2021, with the low at $2.8 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 2.83 Mn |